Abstract: A method of reducing the increased risk of cardiovascular events attendant with the use of COX or selective COX-2 inhibitors including restoring disrupted cholesterol metabolic function engendered by the use of the COX or selective COX-2 inhibitors and reducing the production of foam cells caused thereby. The disrupted cholesterol metabolic function is restored and the production of foam cells is reduced by the step of administering an adenosine A2A receptor agonist having a threshold level of activity of 0.1 μM to a patient using the COX or COX-2 inhibitor. The adenosine A2A receptor agonist is administered orally in amounts sufficient to saturate the A2A receptor and at time intervals sufficient to maintain the restored cholesterol metabolic function.
METHOD FOR IMPROVING CARDIOVASCULAR RISK PROFILE OF COX INHIBITORS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a non-provisional application claiming priority from provisional application No. 61/050,499, filed May 5, 2008 and No. 61/1 15,289, filed November 17, 2008, the disclosures of which are incorporated herein in their entireties, by reference thereto.

FIELD OF THE INVENTION

[0002] This invention relates to methods for protecting the mammalian, including the human, cardiovascular system from the adverse effects of cyclooxygenase (COX) inhibitors including those of selective COX-2 inhibitors.

BACKGROUND

[0003] The association of COX inhibitor NSAIDs (non-steroidal anti-inflammatory drugs), including COX-2 inhibitors, with elevated risk of myocardial infarction and stroke is a major public health concern. The worldwide withdrawal of the selective COX-2 inhibitor, rofecoxib (Vioxx®, Merck) because of adverse cardiovascular events, has complicated clinical decision making for the physician treating patients with pain and inflammation. Whether the benefits of COX-2 inhibitors (also referred to colloquially as "coxibs") and other COX inhibiting NSAIDs outweigh their cardiovascular risks is the subject of an ongoing debate.

[0004] Selective inhibitors of COX-2 are highly effective anti-inflammatory and analgesic drugs that exert their action by preventing the formation of prostanoids. They are used clinically to relieve the symptoms of osteoarthritis and rheumatoid arthritis, and to treat dysmenorrhea.
In September 2004, rofecoxib was withdrawn from the market after clinical trials showed a significant increase in the incidence of adverse cardiovascular events, particularly fatal myocardial infarcions (heart attacks), in rofecoxib-treated subjects compared with placebo. Valdecoxib (Bextra®, Pfizer) was subsequently withdrawn from the market after trials found significantly increased risk of heart attack and stroke. It has become generally known that COX-2 inhibitors, as a class, significantly elevate heart attack and stroke incidence.

The precise mechanisms by which selective inhibitors of COX-2 predispose individuals to cardiac and cerebrovascular disease (stroke) have not been elucidated. Since COX-2-derived prostacyclins exert a cardioprotective effect, the actual increased risk may be related to a decrease in their expression. In fact, one hypothesis to explain the increased cardiovascular risk associated with COX-2 inhibition is the accompanying fall in prostacyclin levels, which may leave arteries more vulnerable to clotting. However, there is a "latent period" before emergence of cardiovascular risk, such as the 18 months prior to the noted increase in incidence of heart attack and stroke in patients treated with rofecoxib, in a Merck funded APPROVe study, that has not been satisfactorily explained or accounted for.

SUMMARY

We have discovered that the use of COX inhibitor NSAIDs, including COX-2 inhibitors, has a disruptive effect on the normal cholesterol metabolic function, with cholesterol not being efficiently cleared from arterial walls. This increase in retained cholesterol was accompanied by increased production of detrimental lipid laden foam cells which attach to arterial walls leading to atherosclerosis and cardiovascular problems including heart attacks, and cerebrovascular problems (stroke). Since atherosclerosis is a condition which worsens over time, the delay or "latent period" before emergence of cardiovascular risk is explainable.

The cholesterol metabolic function involves macrophage cytochrome P450 cholesterol 27-hydroxylase (hereinafter "27-OHase") and other reverse cholesterol
transport (RCT) proteins which counteract cholesterol accumulation by promoting cholesterol efflux. In addition, ATP-binding cassette transporter Al (hereinafter "ABCAI"), an anti-atherogenic integral membrane protein is also a factor in the RCT process.

[0009] We discovered that COX inhibitor NSAIDs and selective COX-2 inhibitors reduce the expression of the RCT proteins 27-OHase and ABCA1 which results in disruption of cholesterol metabolism, to the extent that cholesterol efflux is reduced, cholesterol is retained and lipid laden foam cells are produced. The lipid laden foam cells become attached to arterial walls forming plaque which leads to the adverse cardiovascular condition of atherosclerosis, with increased risk of adverse cardiovascular events such as heart attacks and stroke. We concluded that COX and COX-2 inhibition is an atherogenic effect that may, therefore, contribute to heightened risk of development of atherosclerotic cardiovascular disease (ASCVD) associated with prolonged use of this drug class.

[0010] The present invention relates to a method of reducing the increased risk of cardiovascular and cerebrovascular problems and adverse events in mammals including humans, including those related to atherosclerosis, which may result from the use of selective COX-2 inhibitors or other COX inhibitor NSAIDs. The present invention also relates to a pharmaceutical composition useful in such method. As used herein the term "cardiovascular events" means adverse events such as myocardial infarctions and strokes, attributable to ASCVD and/or disruption of the cholesterol metabolism.

[0011] The method comprises restoring disrupted cholesterol metabolic function engendered by the use of COX or selective COX-2 inhibitors and reducing the production of lipid laden foam cells caused by the use of COX or selective COX-2 inhibitors. The disrupted cholesterol metabolic function is restored and the production of lipid laden foam cells is reduced by administering a pharmaceutically acceptable adenosine A2A receptor agonist having a threshold level of activity or receptor affinity achieved beginning at a concentration of 0.1 µM and optimal at 1 µM to a patient using the COX or selective COX-2 inhibitor. The adenosine A2A receptor agonist is
administered in amounts sufficient to saturate the A2A receptor and at time intervals sufficient to maintain the restored cholesterol metabolic function. As used herein, "administration" of the adenosine A2A receptor agonist also includes administration of a material which effectively results in production in situ of an adenosine A2A receptor agonist.

[0012] The method reduces the increased risk of adverse atherosclerotic cardiovascular and cerebrovascular conditions in a human resulting from the use by the human of a COX or selective COX-2 inhibitor which disrupts a normal cholesterol metabolic function and causes production of lipid laden foam cells. The method comprises restoring disrupted cholesterol metabolic function engendered by COX or selective COX-2 inhibitor, and reducing the production of lipid laden foam cells caused by the use of the COX or COX-2 inhibitor.

[0013] The method also ameliorates atherogenesis in a mammal including human, by administration of an adenosine A2A receptor agonist to the mammal in need thereof in an amount substantially only sufficient to saturate the A2A receptor of the human, wherein atherogenesis in the subject is thereby reduced or prevented.

[0014] The pharmaceutical composition comprises a pharmaceutically acceptable COX or selective COX-2 inhibitor and a pharmaceutically acceptable A2A receptor agonist, with the A2A receptor agonist being present in an amount sufficient to restore cholesterol metabolic function disrupted by the COX or selective COX-2 inhibitor. The pharmaceutical composition of the present invention also comprises a COX or COX-2 inhibitor admixed with an adenosine A2A receptor agonist or a material which effectively results in production in situ of the adenosine A2A receptor agonist. The pharmaceutical composition comprises an analgesic or antiinflammatory effective amount of the COX or COX-2 inhibitor and includes, but is not limited to the standard pharmaceutical dose of the COX or COX-2 inhibitor (e.g., standard doses of commercial Celebrex COX-2 inhibitor are 50, 100, 200 and 400 mg) and an amount of the adenosine A2A receptor agonist sufficient to saturate the A2A receptor. The material (e.g., methotrexate (MTX) which mediates production of the A2A receptor agonist, adenosine
in situ) which effectively results in the production of the adenosine A2A receptor agonist should be present in an amount which effectively results in the adenosine A2A receptor agonist in amounts sufficient to saturate the A2A receptor. The pharmaceutical composition may further include carriers, excipients and other pharmaceutically acceptable materials as normally used in pharmaceutical compositions of the COX or COX-2 inhibitors.

**BRIEF DESCRIPTION OF THE DRAWINGS**

[0015] Figures 1a and 1b are bar graphs showing the reduction effect of celecoxib (Celebrex® Pfizer), selective COX-2 inhibitor at different dose levels, on the gene expression (Fig. 1a) and protein expression (Fig. 1b) of ABCAl, respectively.

[0016] Figures 2a and 2b are bar graphs showing the extent of reduction of 27-OHase (Fig. 2a) and ABCAl (Fig.2b) respectively, caused by the selective COX-2 inhibitor, NS-398 with different dose levels.

[0017] Figures 3a-3d are bar graphs showing the effect of adenosine A2A receptor agonists on 27-OHase levels with combinations of different A2A receptor agonists, and COX-2 inhibitors and the effect of an A2A antagonist on the combinations (Figs 3b and 3c).

[0018] Figures 4a and 4b are bar graphs showing that the ABCAl level effects of A2A agonist CGS-21680 and A2A agonist, methotrexate (MTX), respectively are reduced by an adenosine A2A receptor antagonist.

[0019] Figure 5 is a bar graph showing the effects on 27-OHase levels of NS-398 and MTX at different concentration levels of MTX.

[0020] Figures 6a and 6b are bar graphs of the effects on 27-OHase and ABCAl levels respectively of MTX, an A2A antagonist, atherosclerosis promoting cytokine, EFN-γ, and NS-398 and combinations thereof.
DETAILED DESCRIPTION OF THE EMBODIMENTS

[0021] We found that adenosine A2A receptor agonists, including those currently used in development of asthma and inflammation treatments as well as in myocardial imaging, provide the unexpected effect of substantially reversing the disruption of the RCT process engendered by COX and selective COX-2 inhibitors by increasing the expression of the RCT proteins. The A2A receptor agonists further inhibit production of detrimental lipid laden foam cells which attach to arterial walls resulting plaque deposits and an atherosclerotic condition.

[0022] The amount of the A2A receptor agonist effective in reversing the disruption of the RCT process is minimal and only a fraction of the dosage required in treating asthma, inflammation or for imaging purposes, with the requirement being that the A2A receptor agonist has an A2A receptor agonism activity level in the nanomolar range and is present in sufficient amounts to saturate the high affinity A2A receptor sites. Saturation analysis with [3H]NECA gave a KD-value of 20nM for the human A2A adenosine receptor.

[0023] The activity half life of the specific A2A receptor agonist is determinative of the concurrent dosing thereof with respect to concurrent use of the COX or COX-2 inhibitor. Accordingly, the activity half life of the specific A2A receptor agonist will affect the required frequency of dosing. Dosing with the A2A receptor agonist is only required at time intervals necessary to maintain A2A receptor site saturation. The terminal half-life in rats after an IV dose of CGS-21680 (0.3 mg/kg) is very short (19 ± 4min), but newer drugs have longer half lives than their predecessors.

[0024] Possible side effects with long term usage of the A2A agonists concurrent to dosing use of COX and COX-2 inhibitors are minimized to acceptable risk levels with the small amounts necessary to maintain A2A receptor saturation as well as the extended time periods (depending on A2A agonist half life) required to maintain receptor saturation.

[0025] Although adenosine A2A agonists often have activity at other sites, A2A agonists which are specific to the A2A receptor are likely to have enhanced
efficiency and have minimized side effects which may occur with activation of other adenosine receptors not involved in restoration of the cholesterol metabolic function. Currently, in addition to the existing A2A agonists, with activity at other receptors, new A2A specific agonists have been developed and are at varying stages of approval for use in humans. Except as otherwise indicated the term "A2A receptor agonist" includes materials which function to mediate production in situ of A2A receptor agonists.

[0026] The presently known adenosine receptor subtypes are A1, A2A, A2B and A3 with only activation of the A2A receptor sites being effective in restoring RCT in accordance with the present invention. Adenosine itself however has too short a half life to provide any effectiveness with direct administration. The following are suitable materials effective as A2A receptor agonists in restoring RCT in accordance with the present invention. Materials such as methotrexate (MTX), which is approved for use in humans and is used in cancer treatment in large doses and as the treatment of choice for rheumatoid arthritis (RA) in smaller doses, though not itself an A2A agonist, mediates adenosine release which has activity as an A2A agonist, and thus has activity as an A2A agonist as used herein. Experimentally available CGS-21680 (though not approved for use in humans) is primarily an A2A agonist (though with some activity with other receptors) and is an effective material for use in restoring cholesterol metabolic function.

[0027] Other current A2A receptor agonists in development and/or approved for use in humans and which are useful in the present invention include Binodenoson (CorVueTM), MRE-0094, UK-371,104, ATL 313, Regadenoson (LexiscanTM), Apadenoson, APEC and 2HE-NECA.

[0028] The discussion below describes details of the experimental methods, materials and results used herein.

[0029] The effect of COX inhibition on the expression of several proteins involved in cholesterol efflux in THP-I human monocytes and macrophages was evaluated. We found that pharmacological inhibition of COX-1 and/or COX-2 greatly reduced 27-OHase and ABCA1 expression and that this led to an increase of foam cell formation and an atherosclerotic condition.
Figures Ia and Ib show the reduction of ABCA1 gene expression and protein expression respectively with the use of celecoxib at dose concentrations of 10µM and 50µM, which explains, at least in part, the propensity toward atherogenesis with COX inhibition. The COX-2 selective inhibitor NS-398 markedly diminished 27-OHase and ABCA1 message and protein in THP-I monocytes and macrophages in a dose dependent manner as shown in Figures 2a and 2b respectively. NS-398 reduced 27-OHase mRNA in THP-I to 62.4±2.2% of control (50µM, n=3, p≤0.001). THP-I macrophages treated with NS-398 also showed greater vulnerability to form lipid-laden foam cells compared to untreated cells, with THP-I macrophages showing a significant increase in foam cell transformation in the presence of NS-398 compared to control (42.7±6.6 vs. 20.1±3.4%, p=0.04).

We also discovered that immune reactants interfere with cellular defense against cholesterol overload by diminishing expression of the two proteins responsible for reverse transport of cholesterol out of the cell to the circulation for ultimate excretion: cholesterol 27-OHase and ABCA1, with the atherosclerosis-promoting cytokine IFN-γ decreasing 27-OHase and ABCA1 message and protein expression in THP-I human monocytes/macrophages as shown in Figures 6a and 6b respectively.

Further, IFN-γ-treated THP-I macrophages formed foam cells more rapidly and in greater proportion than untreated control cells. Inhibition of cyclooxygenase (COX) in THP-I monocytes/macrophages acts in a pro-atherogenic manner by dose-dependently decreasing 27-OHase and ABCA1. THP-I macrophages showed a significant increase in foam cell transformation in the presence of the COX-2 selective inhibitor NS-398 compared to control. This indicated that compromise or disruption of reverse cholesterol transport (RCT) contributes to the known increase in cardiovascular risk in patients treated with COX-2 inhibitors.

We discovered that these proteins can be upregulated toward normal cholesterol metabolic function via activation of the adenosine A2A receptor such as with specific A2A agonists including CGS-21680 and MRE-0094. Ligation of the A2A
receptor also inhibited macrophage foam cell transformation under cholesterol loading conditions. We found that methotrexate (MTX) also modulates cholesterol metabolism and vulnerability to foam cell formation and counteracts propensity toward cholesterol overload in THP-I monocytes/macrophages exposed to IFN-γ or selective COX-2 inhibition. MTX provides this protection from atherosclerotic cardiovascular disease (ASCVD) by adenosine release. MTX is not an adenosine A2A receptor agonist but is a source of adenosine which has A2A receptor agonist activity and MTX is accordingly an A2A receptor agonist within the scope of the present invention.

[0034] As discussed in greater detail below, we established that COX-2 inhibitors, as a class, disrupt the known cholesterol metabolic function of the RCT process, with resultant cholesterol retention and production of lipid laden foam cells. Figures 1a and 1b show the effect of celecoxib in reducing ABCAl gene and protein expression as compared to a control. Figures 2a and 2b show the dose dependent continued decrease of 27-OHase in THP-I (Fig. 2a) and the dose dependent continued decrease of ABCAl in THP-I (Fig. 2b) of the COX-2 inhibitor NS-398.

[0035] Further, we established that adenosine A2A receptor agonists restore the cholesterol metabolic function. Figure 3a shows restoration of 27-OHase levels in THP-I by use of A2A agonist CGS-21680. Figure 3c, 3d and 5 show a similar restoration of 27-OHase levels with use of MTX from levels reduced by NS-398. Figure 4b shows restoration by MTX if ABCAl message originally reduced by MS-398.

[0036] We also demonstrated that the activity of the adenosine A2A receptors is responsible for controlling the disruption and restoration of the cholesterol metabolic function. Figure 3b shows the effect of A2A agonist ATL313 in generally raising 27-OHase levels in THP-I. ATL313 increases 27-OHase message in THP-I macrophages andThis sentence is cut off at the end. Please provide the full sentence.
extracted and evaluated for 27-OHase mRNA by QRT-PCR. Amplification of GAPDH message was used as an internal control.

[0037] The 27-OHase and ABCA1 levels were determined with various combinations of selective COX-2 inhibitors, and adenosine A2A receptor agonists (since MTX mediates production of adenosine which has A2A receptor agonist properties, MTX is considered as an A2A agonist herein for simplification).

[0038] NS-398 (an available selective COX-2 inhibitor) was used in the testing as well as celecoxib (the only commercially available selective COX-2 in the US), both of which exhibited cholesterol metabolic function disruption, as discussed. Specific A2A receptor agonists MTX, CGS-21680, MRE-0094 and ATL313 all exhibited restoration of the cholesterol metabolic function. Dispositive confirmation of the sole implication of the A2A receptor activity in the restoration was made with the use of known A2A antagonist ZM-241385 to block A2A receptor sites and with concomitant prevention of the restoration of the cholesterol metabolic function by the A2A agonists used, as shown in Figures 3b-3d, 4a, 4b, 6a and 6b.

[0039] Since MTX is known to affect both adenosine release and cardiovascular risk, MTX was used to determine if it modulates cholesterol metabolism and vulnerability to foam cell formation. We discovered that MTX treatment counteracts propensity toward cholesterol overload in THP-I monocytes/macrophages exposed to IFN-γ or selective COX-2 inhibition. MTX thus provided protection from atherosclerotic cardiovascular disease (ASCVD) by increasing expression of anti-atherogenic molecules involved in cholesterol efflux.

[0040] MTX increases 27-OHase in healthy monocytes isolated from peripheral blood, in addition to use of a monocytic cell line. The peripheral monocytes were primary cells taken directly from the human body and there is evidence of direct physiologic effect by using them.

[0041] Celecoxib or Celebrex (registered trademark of Pfizer Inc.) acts directly on cultured THP-I monocytes to decrease ABCA1. This indicates that results with the COX-2 inhibitor NS-398 are generalizable to other COX inhibitors that are used
in people. A COX-2 silencing study showed that turning off the COX-2 gene by non-pharmacologic methods works as well.

[0042] Celecoxib increases foam cell formation in THP-1 macrophages so not only does celecoxib affect gene expression, it directly impairs the ability of the cell to rid itself of cholesterol and defend itself against lipid overload (the key process that initiates atherosclerotic plaque formation) via a pathway involving adenosine release.

[0043] In addition to MTX, A2A agonist CGS-21680 was also found to increase 27-OHase and ABCAl Message in Murine and Human Monocytes.

[0044] A number of different highly receptor-specific agonists and antagonists of adenosine receptors have been developed that either mimic or block the effects of adenosine. We found that the selective A2A receptor agonist, 2-(4-(2-carboxyethyl)phenethylamino)-5’-N-ethylcarboxamidoadenosine (CGS-21680), at concentrations of 10^{-5}M (3 hours, 37°C, 5% CO2), increases 27-OHase mRNA expression in Balb/C murine macrophages by 47±6.2% (n=3 per group, student t-test, p<0.002). This is believed to be the first demonstration that an endogenous agent upregulates 27-OHase mRNA expression. Based on the upregulation of 27-OHase in murine cells upon exposure to CGS-21680, the same effect was established in human monocytoid cells. In THP-I cells, ABCAl mRNA increased in concert with 27-OHase. THP-I cells were exposed to CGS-21680 in the presence and absence of the A2A receptor antagonist ZM-241385 and it was found that both 27-OHase and ABCA1 message levels failed to rise when the antagonist was present, as shown in Figure 4a.

[0045] In THP-I cells, CGS-21680 increased 27-OHase message in a dose dependent fashion by as much as 1.8-fold. A more selective A2A receptor agonist MRE-0094 also increased 27-OHase (2-fold) and ABCAl (1.8-fold) mRNA expression in THP-I and the A2AR antagonist ZM-241385 reversed the effect of MRE-0094 on both these messages.

[0046] Until recently, major obstacles to the clinical use of A2A receptor agonists included necessity of intravenous administration and short half-life of compounds. Newly developed long acting, orally active A2A receptor ligands include the
promising new agonist ATL313. Consistent with the results with CGS-21680, it was found that ATL313 exerts powerful antiatherogenic effects on THP-I macrophages in culture. ATL313 increases 27-OHase as shown in Figure 3b and ABCAI mRNA and protein in THP-I macrophages and these effects are blocked by ZM-241385.

[0047] In order to prove that only the A2A receptor is specifically implicated in the RCT restoration, the below procedures were conducted.

[0048] CGS-21680 was used as an activator of the adenosine A2A receptor to show reversal of the NS-398 effect on 27-OHase level. This does not however permit the conclusion that ligation of the A2A receptor is responsible for reversing COX-2 effects because CGS-21680 may have other actions such as binding to the A1 receptor.

[0049] In a crucial step further to confirm that the effect is A2A-mediated, loss of the effect occurred when the A2A receptor was blocked by adding A2A antagonist, ZM-241385, which blocked the A2A receptor so that it cannot be turned on. When the COX-2 inhibitor was added with MTX (which causes adenosine release), MTX did not stop the COX-2 inhibitor from decreasing 27-OHase and ABCAI in the presence of ZM-241385. This conclusively indicated that MTX or A2A agonists generally cannot work without access to the A2A receptor.

[0050] Oral dosing and oral active drugs that can be administered to humans - MTX and ATL313 were tested as set forth below.

[0051] Though the effect of the A2A receptor agonist CGS-21680 was examined, it should be noted that use of CGS-21680 maybe inconvenient because CGS-21680 must be infused and at present, is only used experimentally in animals and not in humans. However, both methotrexate and the A2A specific drug ATL313 (developed by Adenosine Therapeutics) are orally active and there are currently a series of ATL adenosine A2A agonists that are either in clinical trials or will be shortly for human use in a variety of disorders. Dosage levels in mice of ATL313 were initially at 5 micrograms/kg every six hours in a murine sepsis model. Subsequent dosage levels were at 30 micrograms/kg/day with the ATL313 being added to their food. A typical MTX
regimen for rheumatoid arthritis in humans would be to start MTX at 10mg/week with
dose escalation to 20-25 mg/week by week 8.

[0052] Decreased Foam Cell Formation was found with MTX as the A2A
agonist and NS-398 as the COX-2 inhibitor tests were conducted as set forth below.

[0053] Lipid overloaded macrophage-derived foam cells play a fundamental
role in all stages of atherosclerosis. A direct physiologic link was shown between the
exposure of macrophages to NS-398 and the ability of the cells to defend against
cholesterol overload. A series of experiments were performed which demonstrated that
foam cell formation from THP-I macrophages in the presence of acetylated LDL
increases dramatically upon exposure to NS-398 and this effect is mitigated by MTX.
Since the mitigation by MTX is due to A2A receptor activation, it was found that ZM-
241385 prevents MTX from decreasing NS-398-induced foam cell formation. The effect
of MTX and NS-398 on cholesterol 27-OHase and ABCAl correlate to a high degree
with the physiologic phenomena seen in lipid-exposed THP-I macrophages.

**Methods: Materials and Sources**

[0054] This section outlines the material, including biologic materials used
throughout all the following experiments in showing: a) cholesterol metabolism
disruption by COX inhibitors; b) restoration of cholesterol metabolism as measured by
27-OHase and ABCAl levels, by use of A2A agonists (including MTX which produces
an A2A agonist *in situ*); and c) that only the A2A receptor is involved in both disruption
and restoration of the cholesterol metabolism as measure by 27-OHase and ABCAl
levels.

[0055] **Cells and reagents:** THP-I monocytes were obtained from ATCC
(Manassas, VA). Oil red O and OptiPrep Density Gradient Media were purchased from
Sigma (St. Louis, MO). Trizol reagent was purchased from Invitrogen (Grand Island,
NY). All reverse transcription- Polymerase chain reaction (RT-PCR) reagents were
purchased from Applied Biosystems, Roche. Recombinant human IFN-γ was purchased
from R&D Systems (Minneapolis, MN). NS-398 was purchased from RBI-Sigma,
Natick, MA. MTX was purchased from Bedford Laboratories, Bedford Ohio. Acetylated LDL was purchased from Intracel (Issaquah, Washington). Anti-cholesterol 27-OHase antibody is an affinity-purified rabbit polyclonal anti-peptide antibody raised against residues 15-28 of the cholesterol 27-OHase protein.

Preparation of Biologic Materials

[0056] Cell culture: THP-I monocytes were grown at 37°C in a 5% CO₂ atmosphere to a density of 10⁶ cells/ml. Growth medium for THP-I cells was RPMI 1640 (GIBCO BRL, Grand Island, NY) supplemented with 10% Fetal Bovine Serum (FBS) (GEBCO BRL), 50 units/ml penicillin, and 50 units/ml streptomycin. To facilitate differentiation into macrophages, THP-I monocytes (10⁶ cells/ml) in 12 well plates were treated with 100nM PMA (Sigma) for 4 days at 37°C.

[0057] PBMC (peripheral blood mononuclear cell) isolation: Blood from healthy donors was collected in EDTA treated tubes, pooled and kept at 4°C. The pooled blood was adjusted to a density of 1.120 g/ml with the addition of OptiPrep Density Gradient Media (Sigma) according to the manufacturer's instructions. The blood was then overlaid with a 1.074 g/ml density solution composed of complete RPMI containing 10% FBS and OptiPrep media. A layer of complete RPMI containing 10% FBS was then overlaid on top to prevent monocytes from sticking to the plastic tube. The blood was centrifuged at 750g for 30 minutes at 4°C. After centrifugation, the monocyte interphase was collected from between the 1.074 g/ml and RPMI layer. The collected cells were diluted with 2 volumes of complete RPMI and harvested by centrifugation. The pellet was re-suspended in complete RPMI. The monocytes were counted by hemocytometer and plated at a density of 2x10⁶ cells/well in a 6-well plate.

Methods: COX inhibitors with Adenosine A2A agonists, antagonists

[0058] THP-I cells: When THP-I cells had reached 10⁶ cells/ml, media was aspirated and cells were rinsed twice with Dulbecco's Phosphate Buffered Saline (DPBS) without calcium and magnesium. The monocytes were then incubated for 24-48 hours in
six well plates, (37°C, 5% CO₂) under the following conditions: a) RPMI control; b) RPMI containing 5mM MTX; c) RPMI containing NS-398 (50µM); d) RPMI containing NS-398 (50µM) and MTX (increasing doses of 0.1µM, 0.5µM and 5µM); e) RPMI containing IFN-γ (500 U/ml); f) RPMI containing IFN-γ (500 U/ml) and 5µM MTX.

[0059] THP-I macrophages were exposed to the following conditions: a) RPMI control; b) RPMI containing ZM-241385 (10µM); c) RPMI containing MTX (5µM); d) RPMI containing IFN-γ (500 U/ml); e) RPMI containing IFN-γ (500 U/ml) and 5µM MTX; f) RPMI containing ZM-241385 (10µM) and MTX (5µM); g) RPMI containing IFN-γ (500 U/ml), ZM-241385 (10µM) and MTX (5µM); h) RPMI containing NS-398 (50µM), ZM-241385 (10µM) and MTX (5µM).

[0060] Immediately after the incubation period, the cells were collected and centrifuged at 1500 RPM at room temperature, media was aspirated and cell protein and RNA were isolated. Figures 6a and 6b graphically depict the OHase and ABCA1 levels obtained.

[0061] PBMC: PBMC were incubated for 18 h in RPMI with 10% FBS with and without the addition of MTX at a concentration of 5µM. Cells were collected and RNA isolated.

[0062] Other experimental conditions of THP-I and PBMC included the following parameters and conditions: when THP-I monocytes had reached 10⁶ cells/ml, media was aspirated and cells were rinsed twice with Dulbecco's Phosphate Buffered Saline (DPBS) without calcium and magnesium. The monocytes were then incubated in six well plates, (37°C, 5% CO₂) under the following conditions: a) RPMI control; b) 10µMNS-398 (18 h); c) 50µMNS-398 (18 h); d) 1µM celecoxib (18 hours); e) 50µM celecoxib (18 h); f) IFN-γ (500 U/ml); g) 50 nM siRNA (24 h); h) 50 nM mock siRNA (24 h).

[0063] THP-1 macrophages were cholesterol-loaded with 50 µg/ml acetylated LDL and incubated an additional 48 hours prior to oil red O staining. Immediately after the incubation period, the cells were collected and centrifuged at 1500 RPM at room temperature, media was aspirated and cell protein and RNA were isolated.
PBMC were incubated for 18 hours in RPMI with 10% FBS with and without the addition of celecoxib at a concentration of 50μM. Cells were collected and RNA isolated.

Results

RNA isolation and quantitation: RNA was isolated using ImI Trizol reagent per 10^6 cells and dissolved in nuclease-free water. The quantity of total RNA from each condition was measured by absorption at 260 and 280 wavelengths using quartz cuvettes by ultraviolet spectrophotometry (Hitachi U2010 spectrophotometer).

RT-PCR analysis of 27-OHase: 27-OHase and ABCAl mRNA were quantitated by real-time PCR. cDNA was copied from 5 μg of total RNA using M-MLV reverse transcriptase primed with oligo dT. Equal amounts of cDNA were taken from each RT reaction mixture for PCR amplification using cholesterol 27-OHase-specific primers or ABCAl specific primers as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control primers. The cholesterol 27-OHase-specific primers span a 311 base-pair sequence encompassing nucleotides 491-802 of the human cholesterol 27-OHase cDNA (24). ABCAl primers yield a 234 BP amplified fragment. Real-time PCR analysis was performed using the SYBR Green PCR Reagents Kit (Applied Biosystems) with a Stratagene MX3005P QPCR System.

PCR was performed using techniques as follows. Each PCR reaction contained 2.5 μl of the 10x fluorescent green buffer, 3 μl of 25 mM MgCl2, 2 μl dNTP mix (2500 μM dCTP, 2500 μM dGTP, 2500 μM dATP, and 5000 μM dUTP), 0.15 μl polymerase (5 U/μl: AmpliTaq Gold; Applied Biosystems), 0.25 μl uracil-N-glycosylase (1 U/μl UNG; AmpErase; Applied Biosystems), 0.5 μl of the forward and reverse primers (10μM concentration), 4 μl cDNA, and water to a final volume of 25 μl. The thermal cycling parameters were as follows: 5 minutes at 95°C to activate the polymerase (AmpliTaq Gold; Applied Biosystems), followed by 45 cycles of 30 seconds at 95°C and 45 seconds at 58°C then 45 seconds at 72°C. Each reaction was done in triplicate.
The amounts of PCR products were estimated, using software provided by the manufacturer (Stratagene). After completion of PCR cycles, the reactions were heat denatured over a 35°C temperature gradient from 60°C to 95°C. To correct for differences in cDNA load among samples, the target PCRs were normalized to a reference PCR involving the endogenous housekeeping genes glyceralddehyde-3-phosphate dehydrogenase (GAPDH) and β-actin. Nontemplate controls were included for each primer pair to check for significant levels of any contaminants. Fluorescence emission spectra were monitored and analyzed. PCR products were measured by the threshold cycles (CT), at which specific fluorescence becomes detectable. The CT was used for kinetic analysis and was proportional to the initial number of target quantity copies in the sample. A melting curve analysis was performed to assess the specificity of the amplified PCR products. The quantity of the samples was calculated after the CTs of the serial dilutions were compared with a control. QRT-PCR standards were prepared by making 1:10 serial dilutions of a purified PCR product.

Western Blots: Total cell lysates were prepared for Western immunoblotting using RIPA lysis buffer (98% PBS, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]). 100µl of RIPA lysis buffer and 1µl of protease inhibitor cocktail (Sigma) were added to the cell pellet from each condition and incubated on ice for 35 minutes with vortexing every 5min. Supernatants were collected after centrifuging at 10,000g at 4°C for 10 minutes using an Eppendorf 5415C centrifuge. The quantity of protein in each supernatant was measured by absorption at 560nm using a Hitachi U2010 spectrophotometer.

Total cell lysate was used for Western blots. Protein samples (20µg/lane) were boiled for 5 minutes, loaded onto a 10% polyacrylamide gel, electrophoresed for 1.5 hr at 100V then transferred to a nitrocellulose membrane in a semi-dry transblot apparatus for 1 hour at 100V. The nitrocellulose membrane was blocked for 4 hours at 4°C in blocking solution (3% nonfat dry milk dissolved in 1xTween20-tris-buffered saline [TTBS]) then immersed in a 1:300 dilution of primary antibody (18.7 µg/ml) in blocking solution overnight at 4°C. The primary antibody is an
affinity-purified rabbit polyclonal anti-peptide antibody raised against residues 15-28 of the cholesterol 27-OHase protein. The following day, the membrane was washed 5 times in TTBS for 5 minutes per wash then incubated at room temperature in a 1:3000 dilution of ECL donkey anti-rabbit IgG Horseradish peroxidase-linked species-specific whole antibody (Amersham Biosciences, product Code NA934). The five washes in TTBS were repeated, then the immunoreactive protein was detected using ECL western blotting detection reagent (Amersham Biosciences, Cat No RPN2106) and film development in SRX-101A (Konica Minolta).

[0071] As a control, on the same transferred membrane, beta-actin was detected using mouse anti-beta-actin (diluted in 1:1000, from abCam, product Code: ab6276) and ECL sheep anti-mouse-IgG Horseradish peroxidase-linked species-specific whole antibody (diluted in 1:2000, from Amersham Biosciences, product Code NA931) and all other similar steps as above.

[0072] **ABCA1 Detection** : For ABCA1 detection, macrophage cell lysates were electrophoresed for 1.5 hr at 100V (10% polyacrylamide gel), then transferred to a nitrocellulose membrane. The membrane was blocked for 4 hours at 4°C in blocking solution then incubated overnight at 4°C in a 1:200 dilution of rabbit anti-ABCA1 antibody (Santa Cruz Biotechnology). The following day, the membrane was washed 5 times in TTBS for 5 mins per wash then incubated at room temperature in a 1:5000 dilution of ECL donkey anti-rabbit IgG Horseradish peroxidase-linked species-specific whole antibody. Development proceeded as described above for the 27-OHase antibody.

[0073] **Foam Cell Analysis** : THP-1 human monocytes (10^6 cells/ml) in 12 well plates were treated with 100nM PMA (Sigma) for 4 days at 37°C to facilitate differentiation into macrophages. The differentiated macrophages were washed three times with phosphate-buffered saline (PBS) and further incubated in RPMI (37°C, 5% CO2) for 48 hr under the following five conditions: a) acetylated LDL (50 µg/ml); b) acetylated LDL (50 µg/ml) and IFN-γ (500LVMl); c) acetylated LDL (50 µg/ml) and EFN-γ neutralizing antibody (1.2 µg/ml); d) acetylated LDL (50 µg/ml), IFN-γ (500LVMl) and
EFN-γ neutralizing antibody (1.2 µg/ml); e) acetylated LDL (50 µg/ml) and IFN-γ receptor antibody (125 ng/ml); f) acetylated LDL (50 µg/ml), IFN-γ receptor antibody (125 ng/ml) and IFN-γ (500 µL/ml).

Immediately following incubation, media was aspirated and cells were fixed in the same 12 well plates used for incubation, with 4% paraformaldehyde in water, for 2-4 min. Cells were stained with 0.2% Oil-Red-0 in methanol for 1-3 min. Cells were observed via light microscope (Axiovert 25-Zeiss) with 100X magnification and then photographed using a Kodak DC 290 Zoom Digital Camera. The number of foam cells formed in each condition were calculated manually and presented as percentage foam cell formation.

Data analysis: Statistical analysis were performed using GraphPad version 4.02 (GraphPad, San Diego, CA). All data were analyzed by one-way ANOVA and pairwise multiple comparisons were made between control and treatment conditions using Bonferroni’s method.

Additional Experiments: THP-I

The THP-1 human monocyte-macrophage cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA). THP-I cells were grown at 37°C in a 5% CO2 atmosphere in the monocyctic form in suspension in RPMI 1640 supplemented with 10% FBS, 50 U/ml penicillin, and 50 µL/ml streptomycin.

When THP-I monocytes reached a density of 1 X 10^6 cells per ml, they were rinsed twice with phosphate-buffered saline (PBS) without calcium and magnesium, then incubated in six well plates (18 hr, 37°C, 5% CO2) in fresh medium under the following conditions: a) RPMI control; b) NS-398 (10-100 µM) for 18 hours; c) CGS-21680 10-5M for 18 hours; d) NS-398 50 µM for 18 hr + CGS-21680 10-5M for 18 hours.

27-OHase and ABCA1 mRNA were quantitated by real-time PCR. cDNA was copied from 5 µg of total RNA using M-MLV reverse transcriptase primed with oligo dT. Equal amounts of cDNA were taken from each RT reaction mixture for
PCR amplification using cholesterol 27-OHase-specific primers or ABCAl specific primers as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control primers. The cholesterol 27-OHase-specific primers span a 311 base-pair sequence encompassing nucleotides 491-802 of the human cholesterol 27-OHase cDNA. ABCAl primers yield a 234 BP amplified fragment. Real-time PCR analysis was performed using the SYBR Green PCR Reagents Kit (Applied Biosystems) with a Stratagene MX3005P QPCR System according to manufacturer's instructions.

[0079] Total cell lysate was isolated for Western immunoblotting using RIPA lysis buffer (98% PBS, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS). 100µl of RIPA lysis buffer and 10µl of protease inhibitor cocktail (Sigma) was added to the cell pellet from each condition, incubated on ice for 35 minutes and vortexed every 5 minutes. Supernatant was collected after centrifuging at 10,000g at 4°C for 10 minutes using an Eppendorf 5415C centrifuge. The quantity of protein in each supernatant was measured by absorption at 560nm using a Hitachi U2010 spectrophotometer.

[0080] As a control, on the same transferred membrane, beta-actin was detected using mouse anti-beta-actin (diluted in 1:1000, from abCam, product Code: ab6276) and ECL sheep anti-mouse-IgG horseradish peroxidase-linked species-specific whole antibody (diluted in 1:2000, from Amersham Biosciences, product Code NA931) and all other similar steps as above.

[0081] Statistical analysis was performed using SigmaStat v2.03 (SPSS, Inc., Chicago, Illinois). Data was analyzed using the Kruskal-Wallis One-Way Analysis of Variance on Ranks. Pairwise multiple comparison was made with the Holm-Sidak method.

Additional Experiments: Foam Cell Formation

[0082] THP-I human monocytes (1 X 10⁶ cells/ml) in 12 well plates were treated with phorbol dibutyrate, 30OnM (Sigma) for 48 hr at 37°C to facilitate differentiation into macrophages. The differentiated macrophages were washed three times with PBS, then incubated alone or in the presence of 10 µM NS-398 (37°C, 5%
Cells were cholesterol-loaded with acetylated LDL (50 µg/ml) and further incubated in RPMI (37°C, 5% CO2) for 48 hours. Studies were performed in triplicate.

Immediately following incubation, media was aspirated and cells were fixed in the same 12 well plates used for incubation, with 4% paraformaldehyde in water, for 2-4 minutes. Cells were stained with 0.2% Oil-Red-0 in methanol for 1-3 min. Cells were observed via light microscope (Axiovert 25-Zeiss) with 1000X magnification and then photographed using a Kodak DC 290 Zoom Digital Camera. The number of foam cells formed in each condition were calculated manually and presented as percentage foam cell formation.

THP-1 moncytoid cells (10^6 cells/ml) were incubated (18hrs, 37°C, 5% CO2) with/without the selective COX-2 inhibitor NS-398 (50µM) in the presence or absence of the A2AR specific agonist CGS-21680 (10µM). RNA were collected directly from the culture dishes using the Trizol reagent and subjected to quantitative real-time PCR for 27-OHase and ABCAl using 5µg of total RNA per condition for reverse transcription with oligo dT primers.

In cultured THP-I human monocytes, NS-398 greatly reduced expression of mRNA for the cholesterol-metabolizing 27-OHase enzyme in a dose-dependent manner. Message level of the cholesterol efflux protein ABCAl is also reduced following NS-398 exposure. Results were confirmed by immunoblot. Addition of an anti-inflammatory adenosine A2AR agonist overcame the reduction in both 27-OHase and ABCAl. Addition of CGS-21680 to NS-398-treated THP-I cells gave rise to a 184% increase in 27-OHase and a 141% increase in ABCAl expression (for 27-OHase: 167.2±8.57% in CGS-21680+NS-398 versus 58.9±2.3% in NS-398 alone, n=3, p<0.001, and for ABCAl : 146.0±3.15% in CGS-21680+NS-398 versus 60.49±4.42% in NS-398 alone, n=3, p<0.001. 100% = baseline expression in untreated THP-I cells).

Discussion of Results
Increased cardiovascular risk with COX-2 inhibition may be ascribed at least in part to disruption of cholesterol outflow which can be corrected via activation of a specific adenosine receptor. These findings provide a novel therapeutic approach targeting the A2AR to decrease the cardiovascular consequences of COX-2 inhibitor therapy in those who require chronic analgesia for arthritic and other inflammatory conditions.

This is the first evidence that any widely used pharmacotherapy can increase the expression of the anti-atherogenic 27-OHase or ABCAl and can counteract the effects of COX-2 inhibition or EFN-γ exposure on gene expression. It was demonstrated that MTX inhibits foam cell formation under conditions of lipid overload. The capacity of MTX to reduce the burden of ASCVD in patients with RA may be ascribed, in part, to favorable alterations in cholesterol homeostasis mediated via activation of the adenosine A2A receptor. Thus, adenosine receptor ligation provides a suitable mechanism for a promising treatment paradigm with long term-benefit in ASCVD.

In order to extend showings of the effects of the A2A agonists on cholesterol metabolism disruption by commercial COX-2 inhibitors, experiments were separately specifically conducted with the COX-2 inhibitor, celecoxib.

CELECOXIB Example and Testing

Celecoxib remains the only available COX-2 inhibitor for treatment of arthritis pain and inflammation in the Unites States. Valdecoxib and Rofecoxib have been withdrawn from the market due to increased evidence of cardiovascular risk.

The exact mechanisms by which COX-2 inhibition may impart increased atherogenic effects has not been elucidated, and concern remains the risk may be a class effect. We showed that selective inhibition of COX-2 with NS-398 downregulates reverse cholesterol transport protein ABCAl, a key regulator involved in ridding cells of cholesterol accumulation. As with other COX-2 inhibitors, Celecoxib exhibited atheroma-promoting properties via compromise of RCT in THP-1 macrophages.
and imparted increased vulnerability to foam cell formation. COX-2 gene silencing appears to adversely affect RCT since both celecoxib and NS-398 suppress RCT through COX-2 inhibition.

[0091] **Methods**: THP-I monocytes (RPMI 1640, 37°C, 5% CO2) were grown to a density of 10^6 cells/ml. THP-I cells were then either subjected to the experimental conditions described or differentiated into adherent macrophages (phorbol dibutyrate, 30OnM, 48 h).

[0092] Media was aspirated and cells were rinsed 3 times with Dulbecco’s Phosphate Buffered Saline (PBS) without Ca++ and Mg ++. The cells were incubated in 6-well plates under the following conditions in triplicate: (1) media alone; (2) 10 µM NS-398 (18 h); (3) 50 µMNS-398 (18 h); (4) 10 µM celecoxib (18 h); (5) 50 µM celecoxib (18 h); (6) 500 U/ml IFN-γ (12 h); (7) 50 nM siRNA (24 h); (8)50 nM mock siRNA (24 h). THP-I macrophages were cholesterol-loaded with 50 µg/ml acetylated LDL and incubated an additional 48 h prior to oil red O staining.

[0093] Cells were collected and centrifuged at 1500 RPM at room temperature, media was aspirated and, cell protein and RNA were isolated (Trizol reagent). The quantity of total RNA from each condition was measured by absorption at 260 nanometer wavelengths using quartz cuvettes by ultraviolet (UV) spectrophotometry (Beckman Coulter DU800).

[0094] RT and PCR reactions were carried out in an Eppendorf master cycler-personal. For each assay 1µg of mRNA was reverse transcribed using Omniscript reverse transcriptase in the presence of 10U of RNase inhibitor and 1 µM oligodT primers. Equal amounts of cDNA were taken from each RT reaction mixture for PCR amplification using both ABCA1 specific primers and glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) control primers. ABCA1 primers yield a 234 bp, GAPDH primers a 357 bp, amplified fragments. The PCR products were loaded directly onto a 2% agarose gel and electrophoresed at 5V/cm for 1.5 hr. DNA was ethidium bromide stained, then visualized and photographed under UV light with a Kodak trans-illuminator. The gel images were photo documented and net intensities were measured with Kodak digital
Cell transfection and COX silencing: Cells were washed 3 times in PBS. Fresh RPMI 1640 (100 ml) was added to each appropriate 8-chamber plate. Cells were incubated in the short time prior to transfection. The following is described per chamber well for a 24 well plate. 375 ng of siRNA (PTGS2 _5 HPV Validated siRNA, Qiagen) was diluted in 100 ml culture medium without serum (final concentration of 50 nM). Addition of 6 ml of HiPerFect Transfection Reagent to the diluted siRNA was followed by vortex mixing. The samples were incubated 5-10 min at room temperature to allow formation of transfection complexes. The complexes were added drop wise onto the cells and swirled to ensure uniform distribution. The cells were then incubated for 6 hr under normal growth conditions. Then 400 ml culture medium containing serum and antibiotics were added, and cells were further incubated for 24-72 hours.

Following incubation, media was aspirated and cells were fixed with 4% paraformaldehyde in water, for 2-4 min. Cells were stained with 0.4% trypan blue for 1-3 min, washed in PBS, and then stained with 0.2% oil-Red-0 in methanol for 1-3 min. Observation and photography of cells was performed respectively via light microscope (NIKON Eclipse TE300) with 4OX magnification and SONY Progressive 3CCD color video camera. The number of foam cells formed in each condition were calculated manually and presented as percentage foam cell formation.

Western Blots: Total cell lysate protein samples (10µg/lane) were boiled for 5 min, loaded onto a 7.5% polyacrylamide gel, electrophoresed for 1.5 hr at 100V then transferred to a nitrocellulose membrane in a semi-dry transblot apparatus for 1 hr at 100V. For ABCA1 detection, the primary antibody was a rabbit anti-human ABCA1 antibody (1:2000 dilution, Santa Cruz Biotechnology). Secondary antibody was ECL donkey anti-rabbit IgG Horseradish peroxidase-linked species-specific whole antibody (1:4000 dilution).
Statistical analysis was performed using Graphpad prism, version 5.01 and SigmaStat version 2.03. Pairwise multiple comparison was made between control and treatment conditions using unpaired t tests, two tailed 95% confidence intervals, significance p<0.05. Foam cell formation was analyzed by Kruskal-Wallis one-way analysis of variance on ranks and pairwise multiple comparison was made with the Holm-Sidak method.

Results: Celecoxib significantly decreased ABCAl message, 50 µM resulted in 65.1% ± 1.5 decrease vs. control, p=0.003. Celecoxib induced ABCAl protein expression decreased in a dose dependent manner, p=0.0002. Transfection with COX-2 siRNA significantly diminished ABCAl message, 22.9% ±4.9 decrease vs. mock, p=0.03.

As shown in Figures 1a and 1b, Celecoxib decreased ABCAl protein expression, 50 µM resulted in decrease of 25.6% ± 1.3 vs. control, p<0.0001. Lipid laden foam cell formation increased with 50 µM Celecoxib, resulting in 95.0%± 0.7 foam cells vs 39.1% ± 5.4 control, p=0.003.

TFP-I macrophages transfected with COX-2 gene silencer had greater propensity to form lipid laden foam cells than mock transfected cells, 58.3% ± 1.6 increase, p=0.003.

Photomicrographs were taken of cholesterol loading with acetylated LDL alone then with 50 µM Celebrex treated cells followed by cholesterol loading with acetylated LDL. This was followed by cholesterol loading with acetylated LDL after mock transfection COX-2 siRNA treated cells followed by cholesterol loading with acetylated LDL.

MTX and CGS-21680 Test Results

MTX (5µM, 18 hr) increased 27-OHase mRNA expression (113.9±6.4%) and completely blocked NS-398-induced downregulation of 27-OHase message (112.8±13.1% for NS-398+MTX versus 71.1±4.3% for NS-398 alone, with untreated as 100%, n=3, p<0.01) (shown in Figure 3d). This ability ofMTXto overcome
suppression of 27-OHase expression by NS-398 was observed at MTX doses of 0.1µM, 0.5µM and 5µM at both the protein and message level (shown in Figure 5).

[0104] MTX was also effective in blocking COX-2 inhibitor-mediated downregulation of ABCA1 message in THP-I monocytes. Adenosine A2A receptor blockade with ZM-241385 abolished the ability of MTX to counter COX-2 inhibitor effects on both 27-OHase (shown in Figures 3c and 4b) and ABCA1. Similarly, downregulation of 27-OHase and ABCA1 by IFN-γ in THP-I monocytes, which we showed previously, was also prevented by MTX and this effect of MTX was negated by ZM-241385 (shown in Figure 6a and 6b).

[0105] Addition of the adenosine A2A receptor agonist CGS-2 1680 to THP-I monocytes exposed to NS-398 overcame the reduction in 27-OHase expression. This was demonstrated by immunoblot and QRT-PCR. Addition of CGS-2 1680 to NS-398-treated THP-I cells gave rise to a 184% increase in 27-OHase mRNA (167.2±8.57% in CGS+NS-398 vs. 58.9±2.3% in NS-398 alone, n=3, p<0.001).

[0106] MTX on foam cell levels: Acetylated LDL-treated THP-I macrophages showed a significant decrease in foam cell transformation in the presence of MTX compared to control (29.7±2.0% vs. 39.3±5.0%, p<0.001). NS-398 treatment resulted in 72.7±4.9% foam cells while combined NS-398+MTX resulted in only 36.3±3.2% foam cells, (n=3, p<0.001). IFN-γ treatment prior to cholesterol loading with acetylated LDL resulted in 71.0±5.0% foam cells while IFN-γ+MTX resulted in only 46.0±7.2% foam cells, (n=3, p<0.001). Preincubation of THP-I macrophages with the selective A2A receptor antagonist (ZM-24 1385) prior to MTX treatment ablated the antiatherogenic effect of MTX and resulted in a significant increase in foam cells (62.1 ±1.5%).

[0107] COX-2 inhibitor-mediated decrease in 27-OHase mRNA is prevented by MTX. THP-1 human monocytes were exposed to the following conditions represented by the four bars (from left to right, FIG. 3d): (1) control RPMI 1640, (2) MTX (5 µM, 18 hr), (3) NS-398 (50µM, 18 hr), (4) MTX (5 µM, 18 hr) and NS-398 (50µM, 18hr). Cells were extracted for total RNA, and evaluated for 27-OHase mRNA expression by
QRT-PCR. Signals obtained from the amplification of GAPDH message were used as
internal controls. *p<0.05, control vs. NS-398. #p<0.01, NS-398 + MTX vs. NS-398 (the
*p and #p notations refer to the p values in the appropriate bar graphs to indicate which
p value fits which bar).

[0108] Detection and quantitation of cholesterol 27-OHase in NS-398-treated
THP-I cells exposed to increasing doses of MTX was examined, revealing a decrease in
27-OHase protein in THP-I monocytes treated with the COX-2 inhibitor NS-398 that
is corrected with increasing concentrations of MTX. Cultured THP-I monocytic cells
were untreated or exposed to NS-398 (50µM, 18hr) then untreated or exposed to
increasing doses of MTX for 24 hr. Total cell protein was isolated and 27-OHase detected
with specific rabbit polyclonal anti-human 27-OHase antibody. Western blotting was also
performed with an anti-beta actin antibody to confirm equal protein loading.

[0109] COX-2-inhibitor-mediated suppression of 27-OHase mRNA expression
in THP-I monocytes is overcome with MTX. Cultured THP-I monocytic cells were
incubated in NS-398 (50µM, 48hr) then untreated or exposed to increasing doses of
MTX for 24 hr. Following isolation of total RNA, the RNA was reverse transcribed and
the cDNA amplified by QRT-PCR as described. Signals obtained from the amplification
of GAPDH message were used as internal controls. *p<0.05, **p<0.01, MTX vs Control
(C). #p<0.01, NS+MTX vs NS-398 (NS).

[0110] Detection and quantitation of cholesterol 27-OHase and ABCA1
mRNA in NS-398-treated THP-I cells exposed to MTX in the presence and absence of
A2A receptor antagonism with ZM-241385 demonstrates that suppression of 27-OHase
message in THP-I cells by NS-398 is reversed by MTX and this reversal is blocked by
ZM-241385. THP-1 monocytes were exposed to the following conditions represented by
the four bars from left to right (FIG. 3c): (1) Control RPMI 1640, (2) NS-398 (50µM,
24 hr), (3) NS-398 (50µM, 24 hr) then add MTX (5 µM, 24 hr), (4) NS-398 (50µM) and
ZM-241385 (10µM) for 24 hr, then add MTX (5µM) for 24 hr. Cells were extracted for
total RNA, and evaluated for 27-OHase mRNA by QRT-PCR. Signals obtained from the
amplification of GAPDH message were used as internal controls.
[0111] It is further demonstrated that suppression of ABCAl message in THP-I cells by NS-398 is reversed by MTX and this reversal is blocked by ZM-241385. THP-I monocytes were exposed to the following conditions represented by the four bars from left to right (Figure 5): (1) Control RPMI 1640, (2) NS-398 (50µM, 24 hr), (3) NS-398 (50µM, 24 hr) then add MTX (5 µM, 24 hr), (4) NS-398 (50µM) and ZM-241385 (10µM) for 24 hr, then add MTX (5µM) for 24 hr. Cells were extracted for total RNA, and evaluated for 27-OHase mRNA by QRT-PCR. Signals obtained from the amplification of GAPDH message were used as internal controls. *p<0.05, **p<0.01, MTX vs control (C). #p<0.01, NS-398+MTX vs NS-398.

[0112] Detection and quantitation of cholesterol 27-OHase mRNA and protein and ABCAl mRNA in IFN-γ-stimulated THP-I cells exposed to MTX in the presence and absence of A2A receptor antagonism with ZM-241385 demonstrated suppression of 27-OHase message in THP-I cells by IFN-γ is reversed by MTX and this reversal is blocked by ZM-241385. THP-I monocytes were exposed to the following conditions represented by the eight bars from left to right (Figures 6a and 6b): (1) Control RPMI 1640, (2) ZM-241385 (10µM, 24 hr), (3) MTX (5 µM, 24 hr), (4) IFN- γ (500 U/ml, 24 hr), (5) IFN- γ (500 U/ml, 24 hr), then add MTX (5µM, 24 hr), (6) ZM-241385 (10 µM, 24 hr), then add MTX (5µM, 24 hr), (7) ZM-241385 (10 µM) and IFN- γ (500 U/ml) for 24 hr, then add MTX (5µM, 24 hr), (8) ZM-241385 (10 µM) and NS-398 (50µM) for 24 hr, then add MTX (5µM, 24 hr). Cells were extracted for total RNA, and evaluated for 27-OHase mRNA by QRT-PCR. Signals obtained from the amplification of GAPDH message were used as internal controls.

[0113] It was further demonstrated that suppression of 27-OHase protein in THP-I cells by IFN-γ is reversed by MTX and this reversal is blocked by ZM-241385. THP-I monocytes were exposed to identical conditions 1-8 as in part (a) of FIG. 6A-6B represented by the eight lanes of the immunoblot from left to right. Total cell protein was isolated and 27-OHase detected with specific rabbit polyclonal anti-human 27-OHase antibody. Western blotting was also performed with an anti-beta actin antibody to confirm equal protein loading.
Additionally, it was found that suppression of ABCA1 message in THP-I cells by IFN-γ is reversed by MTX and this reversal is blocked by ZM-241385. THP-I monocytes were exposed to identical conditions 1-8 as in part (a) of FIG. 6A, represented by the eight bars from left to right. Cells were extracted for total RNA, and evaluated for 27-OHase mRNA by QRT-PCR. Signals obtained from the amplification of GAPDH message were used as internal controls.

CGS-21680: The effect of the A2A agonist CGS-21680 on NS-398-induced suppression of 27-OHase expression in THP-I monocytes was examined, revealing that 27-OHase message level is decreased by the COX-2 inhibitor, NS-398 (50μM), and this decrease is reversed by the addition of the adenosine A2A agonist, CGS-21680 (10 μM). THP-I monocytes were exposed to the following conditions represented by the four bars from left to right (FIG. 3a): (1) Control RPMI 1640, (2) CGS-21680 (10μM, 18 hr), (3) NS-398 (50 μM, 18 hr), (4) NS-398 (50μM, 18 hr) and CGS-21680 (10 μM, 18 hr). Cells were extracted for total RNA, and evaluated for 27-OHase mRNA by QRT-PCR. Signals obtained from the amplification of GAPDH message were used as internal controls. *p<0.01, control vs. NS-398. #p<0.01, NS-398 + CGS-21680 vs. NS-398.

In a further study, THP-I monocytes were exposed to the following conditions: (1) Control RPMI 1640, (2) CGS-21680 (10μM, 18 hr), (3) NS-398 (50 μM, 18 hr), (4) NS-398 (50µM, 18 hr) and CGS-21680 (10 μM, 18 hr) and evaluated by immunoblot for expression of 27-OHase protein. This study demonstrated significant beneficial results. *p<0.01, control vs. NS-398. #p<0.01, NS-398 + CGS-21680 vs. NS-398, and this decrease is reversed by the addition of the adenosine A2A agonist CGS-21680. It has been thus established that 27-OHase protein level is decreased by the COX-2 inhibitor, NS-398, and this decrease is reversed by the addition of the adenosine A2A agonist CGS-21680.

MTX on NS-398 and IFN-γ-induced foam cell transformation in lipid loaded THP-I macrophages: Representative photomicrographs were taken at 40 X magnification of lipid laden macrophages stained with oil red-O. Findings include that:
(a) acetylated LDL-treated THP-I macrophages showed a significant decrease in foam cell transformation in the presence of MTX compared to control; (b) MTX prevented the NS-398-induced increase in foam cell formation in THP-I macrophages; (c) MTX prevented the IFN-γ-induced increase in foam cell formation in THP-I macrophages; and (d) effectiveness of MTX in decreasing foam cell formation is abolished by A2AR antagonism with ZM-241385.

[0118] NS-398 dramatically reduced cholesterol 27-OHase message in THP-1 cells in a dose-dependent manner. This result was confirmed by Western immunoblot. 27-OHase protein expression decreased in the presence of the COX-2 inhibitor NS-398.

[0119] ABCAl message was reduced following NS-398 exposure to approximately 70% of control (50 µM, 71.1±3.9% of control, n=3, p<0.01). This result was confirmed by Western immunoblot.

[0120] Addition of the adenosine A2A receptor agonist CGS-21680 overcame the reduction in both 27-OHase and ABCAl expression (Figure 3a). Addition of CGS-21680 to NS-398-treated THP-I cells gave rise to a 184% increase in 27-OHase mRNA and a 141% increase in ABCAl mRNA (for 27-OHase: 167.2±8.57% in CGS-21680+NS-398 vs 58.9±2.3% in NS-398 alone, n=3, pO.O01, and for ABCAl : 146.0±3.15% in CGS-2 1680+NS-398 vs 60.49±4.42% inNS-398 alone, n=3, pO.O01). 100% = baseline expression in untreated THP-I cells.

[0121] THP-I macrophages treated with the selective COX-2 inhibitor NS-398 showed greater vulnerability to form lipid-laden foam cells compared to untreated cells under conditions of cholesterol-loading with acetylated LDL. THP-I macrophages showed a significant increase in foam cell transformation in the presence of NS-398 compared to control (42.7±6.6 vs 20.1±3.4%, p=0.04).

[0122] THP-I monocyteid cells (10⁶ cells/ml) were incubated (18hrs, 37°C, 5% CO₂) with/without the selective COX-2 inhibitor NS-398 (50 µM) in the presence or absence of the A2AR specific agonist CGS-21680 (10µM). RNA were collected directly from the culture dishes using the Trizol reagent and subjected to quantitative real-time
PCR for 27-OHase and ABCAl using 5µg of total RNA per condition for reverse transcription with oligo dT primers.

[0123] In summary, it has been found that in cultured THP-I human monocytes, NS-3 98 greatly reduced expression of mRNA for the cholesterol-metabolizing 27-OHase enzyme in a dose-dependent manner. Message level of the cholesterol efflux protein ABCA 1 is also reduced following NS-398 exposure. Results were confirmed by immunoblot. Addition of an anti-inflammatory adenosine A2AR agonist overcame the reduction in both 27-OHase and ABCAl. Addition of CGS21680 to NS-398-treated THP-I cells gave rise to a 184% increase in 27-OHase and a 141% increase in ABCAl expression (for 27-OHase: 167.2±8.57% in CGS-21680+NS-398 versus 58.9±2.3% in NS-398 alone, n=3, p<0.001, and for ABCA 1: 146.0±3.15% in CGS-21680+NS-398 versus 60.49±4.42% in NS-398 alone, n=3, p<0.001. 100% = baseline expression in untreated THP-I cells).

[0124] It is understood that the above examples are illustrative of the present invention and that different COX-2 inhibitors or other NSAIDS which disrupt the cholesterol metabolic function, as well as the A2A agonists which restore the function are similarly within the scope of the present invention. It is contemplated that treatments using the present invention could be implemented using any of several routes of administration, including but not limited to central, systemic, peripheral, intravenous, subcutaneous, oral, nasal and/or transdermal routes of administration. Effective routes of administration would thus be readily determined and practiced by those of average skill in the art. Dosage amounts whether absolute or relative as well as times for dosing and the like are similarly variable depending on conditions and patient susceptibility to risk and the like in accordance with the following claims. Proper dosages and treatment regimens would readily be understood and put into practice by one of skill in the art. It is also understood that A2A agonists could be administered in conjunction with, or separately from, COX-2 inhibitors, in either a simultaneous or sequential fashion.

[0125] Although the present invention has been described in relation to particular embodiments thereof, many other variations and modifications and other uses
will readily be apparent to those skilled in the art. It is understood, therefore, that the present invention is not limited by the specific disclosure herein.
WHAT IS CLAIMED IS:

1. A method of reducing the increased risk of adverse atherosclerotic cardiovascular and cerebrovascular conditions in a human resulting from the use by the human of a COX or selective COX-2 inhibitor, the method comprising:

   - restoring disrupted cholesterol metabolic function engendered by a COX or selective COX-2 inhibitor, and
   - reducing the production of lipid laden foam cells caused by the use of the COX or COX-2 inhibitor.

2. The method of claim 1, wherein the disrupted cholesterol metabolic function is restored and the production of lipid laden foam cells is reduced by administering an adenosine A2A receptor agonist having a threshold level of activity of about 0.1µM, to the human using the COX or COX-2 inhibitor.

3. The method of claim 2, wherein the adenosine A2A receptor agonist is administered to the human in amounts sufficient to substantially only saturate the A2A receptor.

4. The method of claim 2, wherein the adenosine A2A receptor agonist is administered to the human at time intervals sufficient to maintain the restored cholesterol metabolic function during the time that the COX or COX-2 inhibitor is being used.

5. The method of claim 2, wherein the adenosine A2A receptor agonist is selected from the group consisting of methotrexate, CGS-21680; ATL 313; Binodenoson; MRE-0094; UK-371,104; Regadenoson; Apecenoson; APEC; and 2HE-NECA.
6. The method of claim 2, wherein the inhibitor is a selective COX-2 inhibitor.

7. The method of claim 6 wherein the selective COX-2 inhibitor is selected from the group consisting of celecoxib, valdecoxib and rofecoxib.

8. The method of claim 5, wherein the COX-2 inhibitor is selected from the group consisting of celecoxib, valdecoxib and rofecoxib.

9. The method of claim 2, wherein the A2A receptor agonist is specific to the A2A receptor.

10. The method of claim 2, wherein the A2A receptor agonist is administered to the human in an oral dose.

11. A pharmaceutical composition comprising a pharmaceutically acceptable selective COX-2 inhibitor and a pharmaceutically acceptable A2A receptor agonist, with the A2A receptor agonist being present in an amount sufficient to restore cholesterol metabolic function disrupted by the selective COX-2 inhibitor.

12. The method of claim 2, wherein the inhibitor is a COX inhibitor.

13. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is formulated for oral administration.

14. A method of reducing the risk of myocardial infarction and stroke in a human to whom COX or selective COX-2 inhibitors are administered, comprising administering to said human an adenosine A2A receptor antagonist.
15. A method of ameliorating atherogenesis in a mammal including a human, comprising: administration of an adenosine A2A receptor agonist to mammal in need thereof in an amount substantially only sufficient to saturate the A2A receptor of the human, wherein atherogenesis in the subject is thereby reduced or prevented.

16. The method of claim 15, wherein the adenosine A2A receptor agonist is selected from the group consisting of methotrexate, CGS-21680, ATL 313, Binodenoson, MRE-0094, UK-371,104, Regadenoson, Apadenoson, APEC and 2HE-NECA.

17. The method of claim 15, wherein the adenosine A2A receptor agonist is administered with sufficient frequency to maintain the human's cholesterol metabolic function.

18. The method of claim 15, wherein the administration is oral.

19. The method of claim 15, further wherein the human is administered an effective therapeutic amount of a selective COX-2 inhibitor.

20. The method of claim 19, wherein the administration of the selective COX-2 inhibitor is simultaneous or sequential with the administration of the adenosine A2A receptor agonist.

21. The method of claim 19, wherein the administration of the selective COX-2 inhibitor with the administration of the adenosine A2A receptor agonist is with sufficient frequency to maintain the human's cholesterol metabolic function.
22. The method of claim 19, wherein the administration of the selective COX-2 inhibitor and the adenosine A2A receptor agonist are oral.

23. The method of claim 19, wherein the selective COX-2 inhibitor is selected from the group consisting of celecoxib, valdecoxib and rofecoxib.

24. A pharmaceutical composition comprising: a pharmaceutically acceptable selective COX-2 inhibitor and a pharmaceutically acceptable A2A receptor agonist, with the A2A receptor agonist being present in an amount sufficient to reduce or prevent atherogenesis in a subject.

25. The pharmaceutical composition of claim 24, wherein the pharmaceutical composition is formulated for oral administration.

26. A method of reducing effect in a mammal resulting from the use by the mammal of a COX or selective COX-2 inhibitor which disrupts a normal cholesterol metabolic function; the method comprising restoring disrupted cholesterol metabolic function engendered by COX or selective COX-2 inhibitor.

27. A method of reducing the increased risk of adverse atherosclerotic cardiovascular and cerebrovascular conditions in a human resulting from the use by the human of a COX or selective COX-2 inhibitor, the method comprising restoring disrupted cholesterol metabolic function engendered by COX or selective COX-2 inhibitor.

28. The method of claim 15 wherein the mammal is a human.
29. The method of claim 1, wherein the COX or selective COX-2 inhibitor disrupts a normal cholesterol metabolic function and causes production of lipid laden foam cells.
Dose-Dependent Decrease in 27-Hydroxylase mRNA with COX-2 Inhibition in THP-1

![Bar graph showing % 27 Hydroxylase mRNA expression](image1)

Figure 2a

COX-2 Inhibition Decreases ABCA1 mRNA in THP-1

![Bar graph showing % ABCA1 mRNA expression](image2)

Figure 2b
The A2AR agonist CGS0-21680 reverses NS398-induced suppression of 27-hydroxylase expression in THP-1 monocytes

![Figure 3a](image-url)

% 27 Hydroxylase/GAPDH mRNA

Control  CGS  NS  CGS+NS

*  #
Effect of ATL313 on 27-hydroxylase message in THP-1

Figure 3b
MTX reverses effect of COX-2 inhibition on 27-hydroxylase message in THP-1 monocytes, but not if an A2A receptor antagonist is present.

![Figure 3c](image)

Effect of MTX on 27-hydroxylase message in THP-1 human monocytes

![Figure 3d](image)
Effect of A2A receptor agonism and antagonism on 27-hydroxylase and ABCA1 message in THP-1 human monocytes

Figure 4a

MTX reverses effect of COX-2 inhibition on ABCA1 message in THP-1 monocytes, but not if an A2A receptor antagonist is present

Figure 4b
MTX overcomes suppression of 27-hydroxylase expression in a dose-dependent fashion in the presence of COX-2 inhibition by NS-398.
A CLASSIFICATION OF SUBJECT MATTER
IPC(8) - G01 N 33/53 (2009.01 )
USPC - 436/87; 436/81 7

According to International Patent Classification (IPC) or to both national classification and IPC

B FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC - 436/87; 436/817

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC- 514/165, 514/406 548/377.1 548/375.1 (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PubWEST(PGPB,USPT,USOC,EPAB,JPAB); Google; PubMed: COX-2, inhibitor, cyclooxygenase, coxib, celecoxib, methotrexate, A2A, cholesterol, cardiovascular, atherosclerosis, atherogenic, foam cell

C DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>KARIM et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Rheumatol. Dec 1999, 26(12):2593-2543; abstract; pg 2540, para 1-2</td>
<td>1-29</td>
</tr>
<tr>
<td>A</td>
<td>US 2007/0032450 A1 (RIEGER) 8 Feb 2007 (08.02.2007)</td>
<td>1-29</td>
</tr>
</tbody>
</table>

D Further documents are listed in the continuation of Box C

* Special categories of cited documents
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
15 June 2009 (15.06.2009)

Date of mailing of the international search report
30 JUN 2009

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:
Lee W Young
PCT Helpdesk 571-272-4300
PCTOSP 571-272-7774